Retrospective Cohort Study

Incidental adenocarcinoma in patients undergoing surgery for stricturing Crohn’s disease

Ivan Kristo, Stefan Riss, Stanislaus Argeny, Svenja Maschke, Praminthra Chitsabesan, Anton Stift

Correspondence to: Stefan Riss, MD, PD, FRCS, Associate Professor, Department of Surgery, Medical University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria. stefan.riss@meduniwien.ac.at

Received: November 1, 2016
Peer-review started: November 2, 2016
First decision: November 21, 2016
Revised: December 7, 2016
Accepted: December 16, 2016
Article in press: December 19, 2016
Published online: January 21, 2017

Abstract

AIM
To evaluate frequency and clinical course of incidental adenocarcinoma in patients with stricturing Crohn’s disease (CD).

METHODS
In this study, consecutive patients, who were operated on for stricturing CD between 1997-2012, were included at an academic tertiary referral center. Demographic data and clinical course were obtained by an institutional database and individual chart review. Besides baseline characteristics, intraoperative findings and CD related history were also recorded. Colorectal cancer was classified and staged according to the Union for International Cancer Control (UICC).

RESULTS
During the study period 484 patients underwent resections due to stricturing CD. Incidental adenocarcinoma was histologically confirmed in 6 (1.2%) patients (4 males, 2 females). Patients diagnosed with colorectal cancer had a median age of 43 (27-66)
years and a median history of CD of 16 (7-36) years. Malignant lesions were found in the rectum (n = 4, 66.7%), descending colon (n = 1, 16.7%) and ileocolon (n = 1, 16.7%). According to the UICC classification two patients were stages as I (33.3%), whereas the other patients were classified as stage II A (16.7%), stage III B (16.7%), stage III C (16.7%) and stage IV (16.7%), respectively. After a median follow-up of 2 (0.03-8) years only 1 patient is still alive.

CONCLUSION
The frequency of incidental colorectal cancer in patients, who undergo surgery for stenotic CD, is low but associated with poor prognosis. However, surgeons need to be aware about the possibility of malignancy in strictureting CD, especially if localized in the rectum.

Key words: Stenosis; Incidental; Colorectal; Crohn’s disease; Cancer; Gastrointestinal

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Incidental colorectal cancer can be expected in 1.2% of patients operated on for strictureting Crohn’s disease. Predominantly, malignant lesions were localized in the rectum and are associated with poor prognosis.

Kristo I, Riss S, Argeny S, Maschke S, Chitsabesan P, Stift A. Incidental adenocarcinoma in patients undergoing surgery for strictureting Crohn’s disease. World J Gastroenterol 2017; 23(3): 472-477. Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i3/472.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i3.472

INTRODUCTION
Patients affected by Crohn’s disease (CD) face a 80% lifetime risk of undergoing a surgical resection[1,2]. Although novel medical strategies have been demonstrated to be effective, the strictureting phenotype still remains a common indication for surgical interventions[3]. Unfortunately, symptoms caused by malignant obstruction are similar to benign strictures in inflammatory bowel disease (IBD). Ruffolo et al[4] assessed the clinical presentation of intestinal adenocarcinoma in CD and concluded that rectal bleeding and weight loss were unrelated to cancer diagnosis. Therefore, personalized endoscopic surveillance plays a crucial role in cancer prevention[5]. Lutgens et al[6] analysed survival rates and tumor stages in IBD related colorectal cancer (CRC) and compared patients that underwent endoscopic screening to no surveillance. Interestingly, 5-year survival rates were significantly superior in the surveillance group, which was explained by cancer detection at an early stage. Nevertheless, a complete endoscopic passage may not be possible as a result of stenotic lumina leading to an incomplete assessment. Importantly, Maykel et al[7] noted that the majority of adenocarcinoma in CD related surgery was not discovered preoperatively but incidentally following surgery.

Incidental postoperative diagnosis of adenocarcinoma after resections for strictureting CD confronts the colorectal surgeon with a fundamental issue. Primarily, strictures in CD are treated as benign and therefore the extent of resection differs from oncologic resections. Limited and inadequate lymph node surgery may be responsible for poor long-term outcomes compared to the general population[8].

Unfortunately, to the authors knowledge, there are hardly any data focusing on incidental adenocarcinoma in strictureting CD[5,9].

The aim of the current study was to evaluate frequency and clinical course of incidental CRC in patients undergoing surgery for strictureting CD.

MATERIALS AND METHODS
Study design
We enrolled consecutive patients, who underwent intestinal resections for symptomatic strictureting CD at a tertiary academic referral center between 1997 and 2012. Disease behaviour was confirmed by perioperative and histological examination.

All surgical procedures were performed or supervised by consultants, who were specialised in the treatment of CD.

Demographic data and information about the clinical course were obtained by an institutional database and by individual chart review, respectively. Besides baseline characteristics, intraoperative findings and CD related history was recorded. Exposure to steroids was defined as steroid intake until the day before surgery. Azathioprin/6-mercaptopurin (AZA/6MP) treatment was registered within 2 wk prior to surgery, whereas anti-tumor necrosis factor (anti-TNF) antibody therapy was documented within 1 wk preoperatively. Furthermore, resections were grouped into simple (1 intestinal resection) and complex (> 1 intestinal resection).

Colorectal cancer was classified and staged according to the Union for International Cancer Control (UICC).

The study was approved by the institutional ethics Committee.

Statistical analysis
Continuous data are shown as mean with standard deviation if normally distributed, or with median and minimum-maximum otherwise. Categorical variables are described with absolute numbers and percentages. Comparison between groups were analysed by Wilcoxon and χ² test when appropriate. All calculations were performed using SPSS for Macintosh, Version 21.0 (IBM Corp., Armonk, NY).
RESULTS

During the study period 484 patients were operated on for symptomatic structuring CD. Further characteristics are listed in Table 1.

Patients underwent an ileocolic resection predominantly. This was performed in 346 (71.5%) patients, followed by 68 (14.0%) colonic resections, 53 (11.0%) small bowel resections and 9 (1.9%) rectal resections. In addition to stricturing disease behavior, 240 (49.6%) patients suffered from fistula, 195 (40.3%) patients from an inflammatory mass, with 104 (21.5%) patients having abscesses. Multiple stenoses were reported in 68 (14.0%) of patients.

Acute resections were performed in 53 (11.0%) patients and 431 (89.0%) of operations were conducted electively. Median operative time was 145 (30-495) min and 233 (48.1%) operations were performed minimal-invasively. Conversion to an open procedure was necessary in 32 (6.6%) patients.

Incidental adenocarcinoma

Colorectal cancer was detected in structuring CD in seven (1.4%) patients. In six (85.7%) of these patients adenocarcinoma was an incidental finding, whereas 1 (14.3%) patient had a preoperative diagnosis of cancer and so was excluded from further analysis. Four males and 2 females were diagnosed with adenocarcinoma at a median age of 43 (27-66) years and a median history of CD of 16 (7-36) years.

Two (33.3%) operations had to be performed acutely due to bowel obstruction and 4 (66.7%) resections were electively because of symptomatic stenotic CD. All six patients had open surgery with a median operative time of 115 (70-199) min.

Four (66.7%) patients had rectal cancer, whereas descending colon (16.6%) and terminal ileum (16.6%) were origin of neoplasia in the other two patients (Table 2).

According to the UICC classification 2 (33.3%) patients had stage I disease, whereas the other four...
patients had stage II A (16.7%), stage II B (16.7%), stage II C (16.7%) and stage IV (16.7%), respectively. After a median follow-up of 2 (0.03–8) years, 5 (83.3%) patients had died and 1 (16.7%) patient was still alive.

Concerning stage I, one patient died 12 d after surgery due to fulminant sepsis. The other patient experienced relapse of adenocarcinoma with palliative chemotherapy and died 8 years after cancer detection.

One patient staged as II A received postoperative chemotherapy but died 2 years after surgery due to cancer recurrence and progression of disease.

All patients with stage III received postoperative chemotherapy. Two years after surgery progression of disease led to early death in one patient, whereas the second patient experienced oxaliplatinum induced acute lung injury and underwent lung-transplantation. She is alive and cancer free 8 years after the incidental finding of cancer.

The patient classified as stage IV received postoperative chemotherapy and died one year after initial diagnosis of cancer due to progression of disease.

Interestingly, preoperative diagnosis of CRC in a chronic stenosis of the rectum with UICC stage II A led to neoadjuvant chemoradiation with subsequent resection in one patient. He is still alive and being treated with palliative chemotherapy for pulmonary metastases 9 years after surgery.

**DISCUSSION**

This is the largest study to date addressing the incidental finding of cancer in patients undergoing surgery for Crohn’s disease. After final histological examination, 1.2% of patients were confronted with diagnosis of adenocarcinoma.

Importantly, these findings are of high clinical value since inflammatory bowel disease is linked to increased mortality due to colorectal cancer12,13. Although an elevated risk for CRC in ulcerative colitis was identified decades ago, data on CRC in CD patients are scarce12,13. A chronic pro-inflammatory environment and cellular damage have been associated with an increased risk of colonic cancer in patients with CD involving the colon13. In cases of paediatric onset, Peneau et al14 have found a higher risk of developing neoplasia. Furthermore, a changing paradigm in medical treatment and its impact on carcinogenesis is still under debate. Interestingly, monoclonal tumor necrosis factor alpha (TNFα) antibodies have established anti-cancer effects while having considerable side effects when administered in therapeutically relevant doses15. In contrast, TNFα antibodies is also secreted by tumors to enhance neoplastic proliferation16. Additionally, immunosuppressive antimetabolites have also been shown to generate mutagenic oxidative DNA damage and may promote malignancy17. Recently, Axelrad et al18 included 333 patients with IBD and history of cancer that subsequently were exposed to anti-TNFα or anti-imatinib antibodies in a prospective study design. They concluded that anti-TNFα or anti-imatinib antibodies were not associated with an increased risk of recurrent or new cancer in this cohort. These findings are comparable with our results, where patients with strictures and no cancer had even higher rates of medical therapy compared to patients with strictures and cancer. One could even speculate that novel potent therapeutic options may break the chain of chronic inflammation and even have beneficial results as far as incidental cancer is concerned. However, our number of cancers was so small that a very large multicenter trial would be needed to power such a hypothesis.

Interestingly, localized, diffuse or multifocal genomic changes precede cancer in IBD19. Point mutation and concomitant inactivation of p53 is associated with malignant transformation in ulcerative colitis20. Even in noncancerous tissue an increased frequency of p53 mutations was present as a consequence of chronic inflammation21.

Therefore, endoscopic surveillance is crucial to decrease risk of neoplasia by detecting pre-neoplastic lesions in patients at risk22. Unfortunately, stricturing CD may lead to incomplete surveillance, especially when multiple stenoses are present. Kamiya et al23 followed 174 consecutive patients diagnosed with CD and revealed 2 cases of adenocarcinoma, which both of which were observed in patients with strictures. Intestinal obstruction was a sensitive symptom in 12 consecutive patients with intestinal adenocarcinoma in CD, as only the minority of patients was diagnosed preoperatively24. Moreover, overlapping clinical presentation may delay therapy and lead to poor prognosis24.

However, our results highlight that personalized endoscopic surveillance is not feasible in all patients with stricturing CD. We currently put further emphasis on the risk of incidental carcinoma especially in older patients with long disease duration that cannot be fully explored by endoscopic means. This strategy may lead to better long-term survival in patients with incidental carcinoma in future.

At present, there are only 2 studies that address the occurrence of CRC in stricturing CD (Table 3). Yamazaki et al9 analyzed 132 patients between 1959

#### Table 3 Studies focusing on incidental finding of adenocarcinoma in patients undergoing surgery for Crohn’s disease

| Patients (n) incidental adenocarcinoma (%) | Risk factors |
|------------------------------------------|--------------|
| Maykel et al[9] (2006)                    | Age, duration and extent of disease |
| Yamazaki et al[9] (1991)                  | Age, duration of disease |
| Furmey et al[8] (2015)                    | No active disease at surgery |
| Kristo et al (present study)              | - |
and 1985 that were admitted with colonic strictures in CD. Importantly, malignant strictures were present in 6.8% and did not show differences in clinical presentation compared to benign strictures. Nevertheless, these results represent a different therapeutic era and do not include incidental findings.

Recently, Fumery et al.[10] assessed frequency of dysplasia and cancer in patients undergoing resection for strictures in IBD. In this multi-center retrospective study 248 patients were included with strictureting disease behavior and screened for dysplasia and cancer. Interestingly, only 2 (0.8%) patients with CD were diagnosed to have cancer, whereas 4 (1.6%) were found to have dysplasia. This rate of intestinal adenocarcinoma is in accordance with our findings at a tertiary academic referral center.

Chronic inflammatory conditions can be misleading in preoperative imaging and result in inadequate surgical resections. As the majority of our incidental CRC findings were located in the rectum, the questions raises, whether patients, who require rectal resection for CD should be operated on oncologically routinely. Especially, patients with extensive disease, long disease duration or diagnosis at an older age, who are at increased risk to develop CRC might benefit from this approach[27]. Importantly, duration of disease is even more important when disease extends over 20 years[30]. These finding are consistent with our cohort, where cancer was diagnosed after a substantial history of CD. Therefore, caution has to be used in the interpretation of strictures of long-standing disease. However, if endoscopic screening fails, active surgical strategies should consider the possibility of incidental cancer.

Unfortunately, long-term survival of patients affected by incidental adenocarcinoma was poor in our analysis. Previously, unfavorable survival was also reported in CD even when the diagnosis of colorectal cancer was established preoperatively[25]. This hower could be due to their co-morbidities, such as the death from fulminant sepsis in a stage I patient or due to the advanced nature of cancer (3 patients stage III or IV) with a number of factors predisposing to this in CD patients.

Although strictureing phenotype is dominated by stenosis, penetrating behaviour may additionally occur. Long-standing anal fistula is an indicator for failed therapy or low medical response, which is an expression of aggressive disease behaviour and leads to prolonged inflammation. Therefore, these patients should be subject to periodic assessment and histological analyses[26]. Importantly, intestinal fistula should be discriminated from perianal fistulating disease, given that they differ in management and outcome[27]. There are hardly any data about cancer originating from extra-anal fistula formation in CD, but one has to be aware of the possibility of incidental cancer manifesting in penetrating CD[30].

Few limitations of this study have to be addressed. Although the current analysis included a very large consecutive cohort of patients, the study was designed retrospectively, thus selection bias cannot be ruled out. Additionally, tertiary referral centers may attract patients with complex clinical conditions, therefore incidental findings of adenocarcinoma may be overrepresented.

In conclusion, Patients, operated on for symptomatic strictureing CD have a low risk for incidental colorectal cancer. However, clinicians need to be aware that the most common location of cancer is in the rectum and that the long-term survival in these patients is low.

**COMMENTS**

**Background**

Most likely, patients that suffer from Crohn’s disease (CD) undergo surgical resections during their course of disease. Strictureting phenotype, a common indication, limits preoperative endoscopic screening that may lead to postoperative diagnosis of incidental adenocarcinoma in resected specimen.

**Research frontiers**

To date there is a lack of data focusing on incidental adenocarcinoma in patients undergoing surgery for strictureing CD. Furthermore, given that benign resections do not include lymph node surgery, a procedure that is considered inadequate in oncologic settings, surgery could be tailored for those areas more likely to have a cancer.

**Innovations and breakthroughs**

The authors found that patients operated on for strictureing CD had a risk of 1.2% to be diagnosed with incidental cancer. Most lesions presented in the rectum and were associated with poor long-term survival.

**Applications**

These findings will influence future clinical recommendations, especially in older patients with a long history of disease that cannot be fully assessed by endoscopic means. Nevertheless, prospective multicenter trials will be needed to raise evidence level and highlight risk factors for incidental cancer.

**Terminology**

According to the Montreal and Vienna classifications, strictureing CD describes a distinct phenotype that is associated with stenosis and can be distinguished from penetrating and non-stricturing, non-penetrating behaviour. Endoscopic screening may be limited in these patients that clinically tend to present with symptoms from gastrointestinal obstruction.

**Peer-review**

Patients with CD of the small and/or large intestine have an increased risk of developing cancer at these sites.

**REFERENCES**

1. **Kristo I**, Stift A, Bergmann M, Riss S. Surgical recurrence in Crohn’s disease: Are we getting better? World J Gastroenterol 2015; 21: 6097-6100 [PMID: 26034346 DOI: 10.3748/wjg.v21.i20.6097]

2. **Riss S**, Schuster I, Papay P, Mittlböck M, Stift A. Repeat intestinal resections increase the risk of recurrence of Crohn’s disease. Dis Colon Rectum 2013; 56: 881-887 [PMID: 23739195 DOI: 10.1097/DCR.0b013e3182e3d3ae]

3. **Yamamoto T**, Watanabe T. Surgery for luminal Crohn’s disease. World J Gastroenterol 2014; 20: 78-90 [PMID: 24415860 DOI: 10.3748/wjg.v20.i1.78]

4. **Ruffolo C**, Scarpa M, Polese L, D’Amico FE, Boetto R, Pozza A, D’Inca R, Checchin D, Sturniolo GC, Bassi N, Aigrinam I. 56 Clinical presentation and diagnosis of intestinal adenocarcinoma in
Crohn’s disease: analysis of clinical predictors and of the life-time risk. J Gastrointest Surg 2010; 14: 1746-1751 [PMID: 20628906 DOI: 10.1007/s11605-010-1265-0]
5 Annese V, Daperno M, Rutter MD, Amiot A, Bossuyt P, East J, Ferrante M, Götz M, Katsanos KJ, Kiedlisch R, Ordás I, Repici A, Rosa B, Sebastian S, Kucharzik T, Eliakim R. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013; 7: 982-1018 [PMID: 24184171 DOI: 10.1016/j.jcc.2013.09.016]
6 Luigens MW, Oldenburg B, Siersema PD, van Bodegraven AA, Dijkstra G, Hommes DW, de Jong DJ, Stokkers PC, van der Woude CJ, Vleggaar FP. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer 2009; 101: 1671-1675 [PMID: 19826420 DOI: 10.1038/sj.bjc.6605359]
7 Maykel JA, Hagerman G, Mellery AF, Li SY, Alavi K, Baxter NN, Maddoff RD. Crohn’s colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis Colon Rectum 2006; 49: 950-957 [PMID: 16729218 DOI: 10.1016/j.dcol.2006.05-555-9]
8 Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD, Velayos F. Incidence and mortality of colorectal adenocarcinoma in patients with inflammatory bowel disease from 1998 to 2010. Gastroenterology 2012; 143: 382-389 [PMID: 22609382 DOI: 10.1053/j.gastro.2012.04.054]
9 Yamazaki Y, Ribeiro MB, Sachar DB, Aufses AH, Greenstein AJ. Malignant colorectal strictures in Crohn’s disease. Am J Gastroenterol 1991; 86: 882-885 [PMID: 2058631]
10 Fumery M, Pinetom de Chambrun G, Stefanesca C, Buisson A, Bressonet A, Beaugerie L, Amiot A, Allweg R, Savoye G, Abihou V, Bouguen G, Simon M, Dufies JP, Hébuterne X, Nancey S, Roblin X, Leteurre E, Bommelier G, Lefevre JH, Brunetti F, Guillou F, Bouthin Y, Peyrin-Biroulet L. Detection of Dysplasia or Guillou in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clin Gastroenterol Hepatol 2015; 13: 1770-1775 [PMID: 26001338 DOI: 10.1016/j.jgh.2015.04.185]
11 Ekborn A, Helmig CG, Zack M, Holmberg L, Adami HO. Survival and causes of death in patients with inflammatory bowel disease: a population-based study. Gastroenterology 1992; 103: 954-960 [PMID: 1499945]
12 Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008; 14: 378-389 [PMID: 18200660 DOI: 10.3748/wjg.v14.i3.378]
13 Ekborn A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990; 336: 357-359 [PMID: 1975343]
14 Peneau S, Savoye G, Turck D, Duachet L, Fumery M, Salleron J, Lerebours E, Liger K, Vasseur F, Dupas JL, Mouterde O, Spyckerelle C, Djeddi D, Peyrin-Biroulet L, Colombel JF, Gower-Rousseau C. Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study. Am J Gastroenterol 2013; 108: 1647-1653 [PMID: 23939626 DOI: 10.1038/ajg.2013.242]
15 Daniel D, Wilson NS. Tumor necrosis factor: renaissance as a cancer therapeutic? Curr Cancer Drug Targets 2008; 8: 124-131 [PMID: 18336195]
16 Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009; 9: 361-371 [PMID: 19340304 DOI: 10.1038/nrc2628]
17 O’Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309: 1871-1874 [PMID: 16166520 DOI: 10.1126/science.114233]
18 Axelrad J, Bernheim O, Colombel JF, Malerba S, Ananthakrishnan A, Yajnik V, Hoffman G, Agrawal M, Lukin D, Desai A, McEachern E, Bosworth B, Scherl E, Reyes A, Zaidi H, Madireddy P, DiCaprio D, Sultan K, Korelitz B, Wang E, Williams R, Chen L, Katz S, Itzkowitz S. Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clin Gastroenterol Hepatol 2016; 14: 58-64 [PMID: 26247146 DOI: 10.1016/j.cgh.2015.07.037]
19 Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016; 22: 4794-4801 [PMID: 27239106 DOI: 10.3748/wjg.v22.i20.4794]
20 Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontonasa M, Newkirk C, Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993; 104: 1633-1639 [PMID: 8507020]
21 Hussain SP, Amstad P, Raja K, Ambis S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 2000; 60: 3333-3337 [PMID: 10910033]
22 Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn’s: a case-control study. Inflamm Bowel Dis 2006; 12: 491-496 [PMID: 16775493]
23 Kamiyta T, Ando T, Ishiguro K, Maeda O, Watanabe O, Hibi S, Mimura S, Ujihara M, Hirayama Y, Nakamura M, Miyahara R, Ohmiya N, Goto H. Intestinal cancers occurring in patients with Crohn’s disease. J Gastroenterol Hepatol 2012; 27 Suppl 3: 103-107 [PMID: 22486881 DOI: 10.1111/j.1440-1746.2012.07082.x]
24 Kersting S, Buerwer M, Laukoetter MG, Rijcken EM, Menningen R, Buerger H, Senninger N, Krieglstein CF. Intestinal cancer in patients with Crohn’s disease. Int J Colorectal Dis 2007; 22: 411-417 [PMID: 16847674 DOI: 10.1007/s00384-006-0164-z]
25 Kavanagh DO, Carter MC, Keegan D, Doherty G, Smith MJ, Hyland JM, Mulcahy H, Sheahan K, O’Connell PR, O’Donoghue DP, Winter DC. Management of colorectal cancer in patients with inflammatory bowel disease. Tech Coloproctol 2014; 18: 23-28 [PMID: 23407916 DOI: 10.1007/s10151-013-0981-3]
26 Zefelipollo A, Costa S, Caprioli F, Contessi-Avesani E. Perianal Crohn’s disease and fistula-associated carcinoma: challenges in diagnosis. Int J Colorectal Dis 2015; 30: 1589-1591 [PMID: 25643850 DOI: 10.1007/s00384-015-2140-y]
27 Kiani QH, George ML, Carapeti EA, Schizas AM, Williams AB. Colovesical fistula: should it be considered a single disease? Ann Coloproctol 2015; 31: 57-62 [PMID: 25960973 DOI: 10.3393/ac.2015.31.2.57]
28 Harisankar CN. Incidentally detected sigmoidovesical fistula in a case of rectosigmoid cancer detected on FDG PET-CT. Clin Nucl Med 2015; 40: e143-e144 [PMID: 24999684 DOI: 10.1097/RLL.0000000000000518]

P-Reviewer: El Rassy E, Hashimoto N, Koch TR, Lakatos PL
S-Editor: Qi Y L-Editor: A E-Editor: Liu WX
